The vast majority of the human genome is transcribed into noncoding RNAs. Among these,
microRNAs (miRNA) and long noncoding RNAs (lncRNA) are frequently deregulated in …

MicroRNA (miRNA) oligonucleotides therapeutics are potent and attractive drugs for cancer
treatment, but the kinetics of their intracellular trafficking, RISC processing and interaction …

Temozolomide (TMZ), an oral alkylating agent, is a cornerstone of standard-of-care
multimodality therapy for glioblastoma. In spite of significant efforts to treat this disease, the …

Glioblastoma (GBM) is the most common type of malignant brain tumor. In spite of recent
advancements in surgical techniques, chemotherapy, and radiation therapy, patients with …

Introduction Glioma is a group of tumors that are usually derived from the glial cells of the
central nervous system and glioblastoma is the deadliest among them. It has a dismal …

Glioblastoma is the most common primary tumor of the central nervous system that develops
chemotherapy resistance. Previous studies showed that Allicin could inhibit multiple cancer …

RNA-binding proteins (RBPs) and miRNAs are critical gene expression regulators that
interact with one another in cooperative and antagonistic fashions. We identified Musashi1 …

Nanomaterials represent a promising and versatile platform for the delivery of therapeutics
to the brain. Treatment of brain tumors has been a long-standing challenge in the field of …

Non-coding RNAs are known to participate in cancer initiation, progression, and metastasis
by regulating the status of chromatin epigenetics and gene expression. Although these non …

A personalized approach to chemoradiation is important in reducing its potential side effects
and identifying a group of patients prone to toxicity. MicroRNAs have been shown to have a …